Cytisine as a smoking cessation aid: Preliminary observations with a modified therapeutic scheme in real life

• Published in: Tumori Vol. 110; no. 2; pp. 124 - 131
• Main Authors: Pozzi, Paolo, Boffi, Roberto, Veronese, Chiara, Trussardo, Sara, Valsecchi, Camilla, Sabia, Federica, Pastorino, Ugo, Apolone, Giovanni, Cardani, Elisa, Tarantini, Francesco, Munarini, Elena
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01-04-2024
• Subjects: Alkaloids - therapeutic use; Azocines - therapeutic use; Benzazepines - adverse effects; Female; Humans; Male; Middle Aged; Nicotinic Agonists - adverse effects; Original s; Quinolizidine Alkaloids; Quinolizines - therapeutic use; Quinoxalines - adverse effects; Retrospective Studies; Smoking Cessation; Varenicline - therapeutic use; varenicline; nicotine addiction; tobacco smoke; anti-smoking center; smoking cessation; cytisine
• ISSN: 0300-8916; 2038-2529
• DOI: 10.1177/03008916231216906

Introduction:
Cigarette smoke accounts for over 90,000 deaths each year in Italy. Tobacco dependence treatment guidelines suggest adopting an integrated pharmacological-behavioral model of intervention. Cytisine is a partial agonist of nicotinic receptors. Trials conducted to date have demonstrated its good efficacy in promoting smoking cessation. The cytisine scheme of treatment consists of 25 days of treatment. A 40-day regimen, with an escalating dose and an extended duration of the treatment, has been in use in many anti-smoking centers in Italy for several years, but to date there are no reports on the use of cytisine with this scheme.
Methods:
A retrospective, real-life, observational study was conducted between January 2016 and September 2022. The 300 patients who had received at least one dose of study medication were selected. Continuous variables were compared by the Wilcoxon-Mann–Whitney test. Univariate and multivariate logistic regression models were implemented for self-reported seven-day point prevalence for abstinence at three, six and 12 months.
Results:
The median age of the patients was 59 years, 57% were women. The median smoking exposure was 33.8 pack-years. Self-reported smoking abstinence at three, six and 12 months was 68.7%, 56.3% and 47.3% respectively. 84% completed the cytisine treatment, 31.3% reported adverse events and in 8.3% these led to dropping out of the treatment.
Conclusion:
Cytisine, administered with a novel therapeutic scheme in the real-life setting of a specialized anti-smoking center, significantly promotes smoking abstinence. However, more studies are needed to assess the tolerability and efficacy of this new regimen.